{"product_id":"dna-ansoff-analysis","title":"(DNA) Ginkgo Bioworks Holdings, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Ginkgo Bioworks Holdings, Inc. Ansoff Matrix Analysis helps you quickly map growth options across market penetration, market development, product development, and diversification in a concise, actionable grid; the page already includes a real preview\/sample so you can judge style and substance. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, research, or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen pharma platform programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks already sells its cell-engineering platform into pharma, so market penetration means winning more programs and bigger repeat work from the same drugmakers. In its latest reported quarter, the company posted $43.4 million in revenue, showing the foundry model still depends on recurring platform use. Deeper account share can lift program volume without needing many new pharma customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand agriculture biologicals adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can lift market penetration by adding more crop and biological-input programs with the same agricultural customers, not by changing the platform or the market. That raises share of wallet in a sector that already uses biologicals to improve yield, resilience, and input efficiency. The move is low-friction and fits the company’s current ag base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncrease specialty chemical manufacturing use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. already serves specialty and sustainable chemicals, so penetration means shifting more current demand from petrochemical routes to its biological platform. In the latest reported year, Company Name posted about $227 million in revenue, showing an installed base that can be mined deeper inside existing accounts. The same strain-engineering platform can swap in bio-based inputs across more products without needing new end markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrow food component collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can push market penetration in food by adding more ingredient and formulation programs with current partners. That fits its existing cell-engineering platform, which already serves food production and vital food components, so the next step is deeper use in the same accounts, not a new market.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Ginkgo Bioworks Holdings, Inc. reported about $227 million in revenue, while the food ingredient market keeps scaling on demand for cleaner labels and better yields. For current food partners, repeat programs can raise wallet share faster than new-customer wins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse current food partners first\u003c\/li\u003e\n\u003cli\u003eAdd more ingredient programs\u003c\/li\u003e\n\u003cli\u003eExpand formulation work per account\u003c\/li\u003e\n\u003cli\u003eIncrease platform use inside food\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrengthen consumer goods ingredient supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumer goods is already a core Ginkgo Bioworks Holdings, Inc. target, so market penetration here means winning more biological ingredient projects from the same brand and manufacturing accounts. That lifts repeat revenue without changing the offering, which is the cleanest form of Ansoff growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore projects per customer\u003c\/li\u003e\n\u003cli\u003eHigher repeat business\u003c\/li\u003e\n\u003cli\u003eLower sales cost per win\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Ginkgo Bioworks Holdings, Inc., this fits a model where the same platform can support enzymes, proteins, and other bio-based ingredients across multiple launches. The main KPI is project density per customer, not new-market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo's Growth Hinges on More Repeat Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can deepen market penetration by adding more repeat programs with current pharma, ag, food, and consumer accounts. In 2025, revenue was about $227 million, so growth depends on higher project density and more wallet share, not new end markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$227M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest quarter revenue\u003c\/td\u003e\n\u003ctd\u003e$43.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eRepeat programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Ginkgo Bioworks Holdings, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix for Ginkgo Bioworks, making growth strategy gaps easy to spot and act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources used to validate Ginkgo Bioworks' growth assumptions across products and markets, enabling fast verification of each Ansoff Matrix path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTake the platform into new pharma subsegments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can push market development by selling the same platform to more pharma buyer groups, not just one therapeutic niche. Its 2024 revenue was about $203 million, so widening use into more drug-discovery and development channels matters for growth. One core platform, more subsegments, bigger addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtend biological design into new food applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks can extend its biological design engine into more food ingredient categories, so the same platform serves new buyers in flavors, proteins, enzymes, and preservation. That is market development: the product base stays familiar, but the customer pool widens into more food makers and ingredient brands. In its latest reported year, Company Name posted revenue of about $227 million, showing the business already has a real industrial base to push into adjacent food uses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter more industrial chemistry use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can use market development to push its sustainable-chemicals platform into more end uses, such as coatings, surfactants, and specialty intermediates. In 2024, Ginkgo reported $203.4 million of revenue, showing it already has a commercial base to extend. The same bio-replacement logic can win new industrial customers where fossil-based inputs still dominate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroaden agriculture reach through new partner types\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks can grow agriculture by selling the same platform to new buyer types, such as seed firms, crop-input makers, and regional agribusiness channels. The tech stays fixed; the go-to-market widens, which is classic market development. In 2025, that matters because agriculture remains a large, fragmented market with many underused channel partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame platform, new buyers\u003c\/li\u003e\n\u003cli\u003eSeed, traits, and input channels\u003c\/li\u003e\n\u003cli\u003eExpand access without rewiring tech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse partner channels to reach new customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks uses partner channels to reach accounts it does not sell to directly, which fits market development in the Ansoff Matrix. Its collaboration with Selecta Biosciences on ImmTOR shows how Ginkgo can scale access through a partner’s customer base while using existing foundry capabilities. As of its latest reported filings, Ginkgo held about $1.0 billion in cash and short-term investments, giving it room to keep building this channel model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led access expands reach fast.\u003c\/li\u003e\n\u003cli\u003eUses existing biology and foundry tools.\u003c\/li\u003e\n\u003cli\u003eFits new customers, not new products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo’s Growth Play: New Buyers, Same Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can drive market development by selling its same platform to new pharma, food, and industrial buyers, not by changing the core tech. Its latest reported revenue was about $203.4 million, and cash and short-term investments were about $1.0 billion, which supports wider channel reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest revenue\u003c\/td\u003e\n\u003ctd\u003e$203.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and short-term investments\u003c\/td\u003e\n\u003ctd\u003e~$1.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket development focus\u003c\/td\u003e\n\u003ctd\u003eNew buyers, same platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eGinkgo Bioworks Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, showing market penetration, product development, market development, and diversification strategies tailored to Ginkgo Bioworks. Buy now to unlock the complete, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance the ImmTOR technology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. and Selecta Biosciences are jointly advancing ImmTOR, a clear product-development move because it adds a new pharmaceutical platform to Ginkgo Bioworks Holdings, Inc.'s portfolio, not just more engineering services. ImmTOR has been tested in clinical programs, so the focus is on a higher-value biologic delivery platform with real drug-development upside.\u003c\/p\u003e\n\u003cp\u003eThis fits Ansoff product development: same broad biotech market, new technology offering, and deeper monetization potential if ImmTOR reaches broader partnering or licensing use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCreate new engineered cell programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProduct development fits Ginkgo Bioworks Holdings, Inc. because its platform is built to reprogram cells and produce new biological outputs for existing markets. New engineered cell programs let the Company add new end uses without changing its core model, which is the classic Ansoff path for deeper product breadth. This matters because each new program can be sold into the same biotech, food, and industrial customer base, raising reuse of its foundry system.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop new sustainable chemical pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can use product development to create new biological routes and engineered strains for more sustainable chemicals, while keeping the same industrial buyers. This is a good fit because the market stays the same, but the output changes from one molecule to another. The IEA says chemicals use about 4% of global final energy and cause about 5% of energy-related CO2, so even small shifts to bio-based routes can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBuild new food ingredient solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProduct development fits Ginkgo Bioworks Holdings, Inc. by turning its existing food-production and food-component customers into buyers of new biological ingredient lines. In 2025, the company kept using one platform to design and scale repeatable products, which lowers R\u0026amp;D reuse costs and speeds follow-on launches. That matters in a market where a single ingredient can move from pilot to multiple SKUs fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses one platform for many ingredients\u003c\/li\u003e\n\u003cli\u003eSells to current food customers\u003c\/li\u003e\n\u003cli\u003eSupports successive product lines\u003c\/li\u003e\n\u003cli\u003eRaises reuse, lowers launch friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEngineer new agricultural biologicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProduct development fits Ginkgo Bioworks Holdings, Inc.’s agriculture base: it adds new engineered microbes and biological inputs for crop use inside the same market. Crop biologicals are still a fast-growing niche, with the global market estimated at about $15 billion in 2025, so the move can deepen wallet share without needing a new customer set.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, new products\u003c\/li\u003e\n\u003cli\u003eHigher crop-input mix\u003c\/li\u003e\n\u003cli\u003eUses Ginkgo’s biology platform\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo Expands by Adding Higher-Value Bio Products to Existing Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. uses product development to sell new biological products to existing biotech, food, and agriculture customers. ImmTOR adds a higher-value platform, while engineered microbes and ingredients reuse the same foundry model, so the Company grows by broadening output, not customer reach. In agriculture, crop biologicals were about $15 billion in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eCrop biologicals\u003c\/td\u003e\n\u003ctd\u003eAbout $15 billion\u003c\/td\u003e\n\u003ctd\u003eSupports new product lines in the same market\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePair cell engineering with immune-tolerance tech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmTOR with Selecta Biosciences gives Ginkgo Bioworks Holdings, Inc. a second layer beyond cell engineering, moving into adjacent therapeutic-platform work. That is diversification in Ansoff terms: a new product path aimed at a different buyer need, not just more service volume. The move can widen Ginkgo Bioworks Holdings, Inc. exposure from platform fees to higher-value drug-development use cases, if the biology and economics hold.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServe food and consumer goods together\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks already works across food production and consumer goods, so this is diversification, not a new lane. Its foundry model lets it design new biological outputs for two different market sets at the same time, which fits a 2025-2026 cross-market growth play. The platform breadth is the key asset: one R\u0026amp;D engine can serve multiple end uses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlend agriculture with industrial biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. can use its agriculture work and chemicals platform to cross-sell crop-input tools and industrial bio-manufacturing outputs, which is classic diversification into new products and new markets. In 2024, Ginkgo reported $203 million in revenue, with biosecurity $77 million and cell engineering $126 million, showing a still-small but broad base across sectors. That mix supports moving from one market into multiple product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpand beyond single-sector customer models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks uses one engineering platform across five end markets: pharmaceuticals, agriculture, food, consumer goods, and chemicals. That is the diversification play in the Ansoff Matrix: one R\u0026amp;D engine, many revenue pools, so the same foundry can sell into different demand cycles. The breadth of the platform is the edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne platform, five customer bases\u003c\/li\u003e\n\u003cli\u003eSpreads sector-specific demand risk\u003c\/li\u003e\n\u003cli\u003eMonetizes shared bioengineering IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLink pharma programs to broader bio-manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks can tie pharma programs to industrial and food work because the same cell-engineering platform serves 3 end markets. That diversification lowers reliance on any one sector and can smooth demand when pharma timing shifts. One platform, multiple revenue paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame core capability, 3 markets\u003c\/li\u003e\n\u003cli\u003eLess dependence on pharma spend\u003c\/li\u003e\n\u003cli\u003eBroader use of R\u0026amp;D assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo’s Diversification Spans Biosecurity and Cell Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification at Ginkgo Bioworks Holdings, Inc. is its push from one bioengineering core into pharma, agriculture, food, consumer, and chemicals. In 2024, revenue was $203 million: $77 million biosecurity and $126 million cell engineering, so the platform already spans multiple demand pools. That mix can reduce reliance on any single sector.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$203M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosecurity\u003c\/td\u003e\n\u003ctd\u003e$77M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell engineering\u003c\/td\u003e\n\u003ctd\u003e$126M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234351063305,"sku":"dna-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dna-ansoff-matrix.webp?v=1785716938","url":"https:\/\/dcfanalyst.com\/products\/dna-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}